Photo from wikipedia
This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type… Click to show full abstract
This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF).
Keywords:
heart failure;
dkd trial;
analysis fidelio;
fidelio dkd;
heart
Journal Title: European Journal of Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!